Triple-Negative Breast Cancer A Short Review

被引：111

作者：

Elias, Anthony D. ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, Aurora, CO 80045 USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2010年 / 33卷 / 06期

关键词：

triple-negative; breast cancer; review; GROWTH-FACTOR RECEPTOR; BASAL-LIKE SUBTYPE; DNA-REPAIR DEFECT; ESTROGEN-RECEPTOR; PHASE-II; CARCINOMAS; EXPRESSION; BRCA1; SURVIVAL; CHEMOSENSITIVITY;

D O I：

10.1097/COC.0b013e3181b8afcf

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This review describes the pathology, prognosis, current treatment options, and future directions for the management of patients with triple-negative breast cancer. "Triple-negative" tumors lack expression of estrogen and progesterone receptors, and HER2. The subtype comprises some 15% of all breast cancers, with tumors of a typically larger size and higher grade. Clinically, triple-negative breast cancer has a relatively high rate of recurrence and distant metastasis, and poor overall survival. The standard of care is chemotherapy, although recent research suggests a sound rationale for the use of targeted agents with antitumor and/or antiangiogenic activity such as receptor tyrosine kinase inhibitors.

引用

页码：637 / 645

页数：9

共 62 条

[1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].

Abd El-Rehim, DM ;

Ball, G ;

Pinder, SE ;

Rakha, E ;

Paish, C ;

Robertson, JFR ;

Macmillan, D ;

Blamey, RW ;

Ellis, IO .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350

[2]

ADEBAMOWO CA, 2006, J CLIN ONCOL, V24, pS568

[3] Basal-like breast carcinomas: clinical outcome and response to chemotherapy [J].

Banerjee, S. ;

Reis-Filho, J. S. ;

Ashley, S. ;

Steele, D. ;

Ashworth, A. ;

Lakhani, S. R. ;

Smith, I. E. .

JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (07) :729-735

[4] Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].

Bauer, Katrina R. ;

Brown, Monica ;

Cress, Rosemary D. ;

Parise, Carol A. ;

Caggiano, Vincent .

CANCER, 2007, 109 (09) :1721-1728

[5] The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].

Bhattacharyya, A ;

Ear, US ;

Koller, BH ;

Weichselbaum, RR ;

Bishop, DK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903

[6] Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].

Burstein, Harold J. ;

Elias, Anthony D. ;

Rugo, Hope S. ;

Cobleigh, Melody A. ;

Wolff, Antonio C. ;

Eisenberg, Peter D. ;

Lehman, Mary ;

Adams, Bonne J. ;

Bello, Carlo L. ;

DePrimo, Samuel E. ;

Baum, Charles M. ;

Miller, Kathy D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816

[7]

Carey LA, 2007, BREAST CANCER RES TR, V106, pS32

[8] The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].

Carey, Lisa A. ;

Dees, E. Claire ;

Sawyer, Lynda ;

Gatti, Lisa ;

Moore, Dominic T. ;

Collichio, Frances ;

Ollila, David W. ;

Sartor, Carolyn I. ;

Graham, Mark L. ;

Perou, Charles M. .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334

[9] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].

Carey, Lisa A. ;

Perou, Charles M. ;

Livasy, Chad A. ;

Dressler, Lynn G. ;

Cowan, David ;

Conway, Kathleen ;

Karaca, Gamze ;

Troester, Melissa A. ;

Tse, Chiu Kit ;

Edmiston, Sharon ;

Deming, Sandra L. ;

Geradts, Joseph ;

Cheang, Maggie C. U. ;

Nielsen, Torsten O. ;

Moorman, Patricia G. ;

Earp, H. Shelton ;

Millikan, Robert C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502

[10] Overexpression of platelet-derived growth factor receptor a in breast cancer is associated with tumour progression [J].

Carvalho, I ;

Milanezi, F ;

Martins, A ;

Reis, RM ;

Schmitt, F .

BREAST CANCER RESEARCH, 2005, 7 (05) :R788-R795

← 1 2 3 4 5 6 7 →